Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

INNA-051

Phase 2Small molecule

EENA Respiratory Pty Ltd

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory InfectionRecruiting

Respiratory InfectionPhase 2

Recruiting

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Respiratory Infection

NCT07222670

Clinical

Trials by Indication[1]

COVID-191 trial

Intranasal INNA-051 for Prevention of COVID-19 in Adults

Withdrawn·EENA Respiratory Pty Ltd·Phase 2·NCT05118763

Influenza1 trial

INNA-051 Influenza Challenge Study

Completed·EENA Respiratory Pty Ltd·Phase 2·NCT05255822·123 enrolled

Respiratory Infection1 trial

A Randomized, Double-Blind, Two-Part, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of INNA-051 as Prophylaxis for Respiratory Tract Illness in Healthy Adults 18 to 45 Years of Age Who Are at Risk for Viral Respiratory Infections

Recruiting·EENA Respiratory Pty Ltd·Phase 2·NCT07222670·1,100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for INNA-051. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INNA-051 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INNA-051. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ENA Respiratory Pty Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EENA Respiratory Pty Ltd

Related News